Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 65 years of age.~* Healthy.~* Subject is a nonsmoker.~* Subject's body mass index (BMI) is \>=18 kilogram/meter square (kg/m\^2) and \<=30 kg/m\^2~* Male or~* Female~Exclusion Criteria:~* Alanine aminotransferase (ALT) \>1.5 x upper limit of normal range (ULN)~* Bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent \[%\]).~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (msec).~* Systolic blood pressure is \>=140 millimeter of mercury (mmHg) at Screening;~* Diastolic blood pressure is \>=90 mmHg at Screening;~* Heart rate is \>100 beats/min at Screening.~* estimated glomerular filtration rate (eGFR) \<=80 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) (calculated using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula) at Screening.~* Fasting triglyceride level \>300 milligram per deciliter (mg/dL) at Screening.~* History of significant cardiovascular or pulmonary dysfunction prior to Screening.~* History of thyroid dysfunction or an abnormal (i.e., outside the normal reference range) thyroid function test assessed by thyroid stimulating hormone at Screening.~* History of gastrointestinal surgery that could influence gastric emptying (e.g., gastrectomy, gastric bypass).~* History of pancreatitis.~* Personal or family history of multiple endocrine neoplasia type 2.~* Personal or family history of medullary carcinoma of the thyroid.~* Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days.~* History of regular alcohol consumption within 6 months of the study.~* Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.~* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.~* Subject has previously received any GLP-1 mimetic compound (eg., exenatide, liraglutide, lixisenatide, dulaglutide).~* Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.~* A positive pre-study drug/alcohol screen.~* A positive test for human immunodeficiency virus (HIV) antibody.~* Subject has donated blood in excess of 500 mL within 56 days prior to dosing or intention of donating in the month after completing the study.~* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~* Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Regimen AB (Type: EXPERIMENTAL): Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2.
- Regimen BA (Type: EXPERIMENTAL): Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).